Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomics biomarkers.

Researchers ID Low Immune Cell Responsiveness and High Level of Proteins as Features of COVID-19 Severity

Article title: Chemokines, soluble PD-L1 and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illness Authors: Eric D. Morrell, Pavan K. Bhatraju, Neha A. Sathe, Jonathan Lawson, Linzee Mabrey, Sarah E. Holton, Scott R. Presnell, Alice Wiedeman, Carolina Acosta-Vega,…